Bobcatbio, Inc.
Hummelstown, PA Sirpant Immunotherapeutics Inc.
- UEI
- H7HGMZ5YTLQ6
- CAGE
- 8PDQ9
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1214 Research Blvd #2010, Hummelstown, PA 17036, USA
- Website
- sirpantimmunotx.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sirpant technology for anti-cancer immunity | National Cancer Institute (NIH) | $3,199,999 |
Quick answers
Is Bobcatbio, Inc. registered in SAM.gov?
Yes. Bobcatbio, Inc.'s SAM.gov registration is active through April 23, 2027.
What is Bobcatbio, Inc.'s most recent federal award?
Bobcatbio, Inc.'s most recent federal grant award is Sirpant technology for anti-cancer immunity (R42CA265691), from National Cancer Institute (NIH), on September 22, 2021.
On GovTribe
See Bobcatbio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors